Management of anaemia and other treatment complications

Digestive and Liver Disease

Volumn 45, Issue S5, 2013, Pages

  Hézode, Christophe ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

Anaemia; Hepatitis C; Protease inhibitor; Rash

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; PEGINTERFERON; PLACEBO; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANUS PRURITUS; BLOOD TRANSFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSGEUSIA; ECZEMA; FATIGUE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; NAUSEA; NEUTROPENIA; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; XEROSIS;

ANAEMIA; HEPATITIS C; PROTEASE INHIBITOR; RASH;

ANEMIA; ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; DYSGEUSIA; HEMORRHOIDS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; OLIGOPEPTIDES; PATIENT SELECTION; PLATELET COUNT; POLYETHYLENE GLYCOLS; PROLINE; PRURITUS ANI; RIBAVIRIN; SERUM ALBUMIN;

EID: 84884727538     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.010     Document Type: Review

References (26)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005, 5:558-567.
2. Poynard T., Mchutchison J., Manns M., et al. Impact of peylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
3. Shiratori Y., Ito Y., Yokosuka O., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Annals of Internal Medicine 2005, 142:105-114.
4. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002, 347:975-982.
5. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine 2009, 361:580-593.
6. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, 55:245-264.
7. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis c virus infection. New England Journal of Medicine 2011, 364:2405-2416.
8. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
9. Telaprevir EU Summary of Product Characteristics [online]. Available at http://www.ema.europa.eu/.
10. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
11. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
12. Boceprevir EU Summary of Product Characteristics [online]. Available at http://www.ema.europa.eu/.
13. Sulkowski M.S., Reddy R., Afdhal N.H., et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the advance and illuminate phase 3 studies. Journal of Hepatology 2011, 54(Suppl. 1):S195.
14. Sulkowski M.S., Poordad F., Manns M.P., et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013, 57:974-984.
15. Shiffman M.L., Ghany M.G., Morgan T.R., et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103-112.
16. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
17. Poordad F., Lawitz E., Reddy K.R., et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. Journal of Hepatology 2012, 56(Suppl. 2):S559.
18. Lawitz E., Zeuzem S., Nyberg L.M., et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/RBV) in treatment-naive chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response (SVR) and safety subanalyses from the anemia management study. Hepatology 2012, 56(Suppl):216A.
19. Sulkowski M., Roberts S., Afdhal N., et al. Ribavirin dose reduction in treatment naive and previously treated patients who received telaprevir-combination treatment: no impact on SVR in phase 3 studies. Journal of Hepatology 2012, 56(Suppl. 2):S459-S460.
20. Lübbe J., Kerl K., Negro F., et al. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. British Journal of Dermatology 2005, 153:1088-1090.
21. Lübbe J. Dermatological side effects. Hot Topics in Viral Hepatitis 2008, 9:29-35.
22. Cacoub P., Bourlière M., Lübbe J., et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. Journal of Hepatology 2012, 56:455-463.
23. Montaudié H., Passeron T., Cardot-Leccia N., Sebbag N., Lacour J.P. Drug rash with eosinophillia and systemic symptoms due to telaprevir. Dermatology 2010, 221:303-305.
24. Hettiaratchy S., Papini R. Initial management of a major burn: II - Assessment and resuscitation. British Medical Journal 2004, 329:101-103.
25. Pol S., Roberts S.K., Andreone P., et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology 2011, 54:374A-375A.
26. Hézode C., Fontaine H., Dorival C., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC). Journal of Hepatology 2013, May 10 [Epub ahead of print].